Enzymatic Changes in Serum of Benign and Malignant Brain Tumors Patients

ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival

“…The stability of the ssDNA NT in different conditions is therefore promising for their in vivo use. The average concentration of circulating DNase I in healthy human patients is 0.356 ± 0.410 U/ml, while the circulating concentration of DNase I in human patients with GBM is 0.045 ± 0.007 U/ml ( 41 , 42 ). Therefore, even at much higher than physiologically relevant concentrations of DNase, the ssDNA-amphiphile NT show no degradation.…”